Therapeutic Asset Ratings

151 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
e-602 Cancer	Palleon Pharmaceuticals, Inc.	P1/2	CC (44)
H-gamma1 heavy chain Homo sapiens (1-447) [VH (Homo sapiens IGHV4-5901 (99.0%) -(IGHD) -IGHJ302 (93.3%) T125>I (114), CDR-IMGT [8.7.11] (26-33.51-57.96-106)) (1-117) -Homo sapiens IGHG101, G1m17,1 CH1 K120, CH3 D12, L14, 9-G1v21 CH2 Y15.1, T16, E18 (CH1 K120 (214) (118-215), hinge 1-15 (216-230), CH2 M15.1>Y (252), S16>T (254), T18>E (256) (231-340), CH3 D12 (356), L14 (358) (341-445), CHS (446-447)) (118-447)], (220-214')-disulfide with L-kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV3-1101 (96.8%) -IGKJ401 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC01 (100%) Km3 A45.1, V101 (CKAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (226-226'':229-229'')-bisdisulfide, produced in a cell line derived from Chinese hamster ovary (CHO) cells, glycoform alfa Cancer	Kineta Inc.	P1/2	CC (44)
FAPi-46 Cancer	Eben Rosenthal	P1	CC (42)
161Tb-NYM032 Cancer	Zhengguo Chen	P1/2	CC (41)
68Ga-NODAGA-SNA006 Cancer	First Hospital of China Medical University	P1/2	CC (41)
a2b395 Cancer	A2 Biotherapeutics Inc.	P1/2	CC (41)
a2b530 Cancer	A2 Biotherapeutics Inc.	P1/2	CC (41)
a2b543 Cancer	A2 Biotherapeutics Inc.	P1/2	CC (41)
a2b694 Cancer	A2 Biotherapeutics Inc.	P1/2	CC (41)
Acit-1 Cancer	Cancer Vaccines Limited	P1/2	CC (41)
Dual-Target Antigen-Selected Car-Nk Cancer	Essen Biotech	P1/2	CC (41)
EBNK-001 Cancer	Essen Biotech	P1/2	CC (41)
Eb-Select Single-Target Car-Nk Cells Cancer	Essen Biotech	P1/2	CC (41)
Fog-001 Cancer	Parabilis Medicines, Inc.	P1/2	CC (41)
gfh276 Cancer	Genfleet Therapeutics (Shanghai) Inc.	P1/2	CC (41)
il-15 Cancer	Essen Biotech	P1/2	CC (41)
ima402 Cancer	Immatics Biotechnologies GmbH	P1/2	CC (41)
Interleukin 18 (recombinant human mutein clone ST-067) Cancer	Simcha IL-18, Inc.	P1/2	CC (41)
jk08 Cancer	Salubris Biotherapeutics Inc	P1/2	CC (41)
LENVATINIB Cancer	Salubris Biotherapeutics Inc	P1/2	CC (41)
Obinutuzumab Cancer	Simcha IL-18, Inc.	P1/2	CC (41)
or502 Cancer	OncoResponse, Inc.	P1/2	CC (41)
PSMA I&T Cancer	CHU de Quebec-Universite Laval	P1/2	CC (41)
Sarilumab Cancer	University of Southern California	P1/2	CC (41)
vb15010 Cancer	Zhejiang Yangli Pharmaceutical Technology Co., Ltd.	P1/2	CC (41)

Showing 76 to 100 of 151 assets

PreviousPage 4 of 7Next